Compare Eos Energy Enterprises Inc (EOSE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Sana Biotechnology Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.52 (market cap $1.01B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Eos Energy Enterprises Inc is the larger of the two by market cap, and Eos Energy Enterprises Inc is more actively traded (39,626,541 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Sana Biotechnology Inc for 23 Days on average.
| EOSE | SANA | |
|---|---|---|
Market Cap | $1.01B | $836.71M |
Volume | 39,626,541 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $19.19 | $5.92 |
52-Week Low | $2.52 | $2.68 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $1.34B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.765, down 10.81% on the day, reflecting a bearish technical trend. The company is in a high-growth phase, with revenue surging from $114 million in 2025 to $214 million in 2026, but it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.
The outlook is a high-risk, high-reward proposition. Analyst consensus is a 'Buy' with a $7.10 price target, implying significant upside, but this is contingent on the company achieving profitability as it scales. Key risks include persistent cash burn, intense competition in energy storage, and execution challenges in ramping production.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
